Immunovant, Inc.
NASDAQ:IMVTBiotechnology
+$0.69 today
- Market cap
- $6.87B
- Beta
- 0.79
- P/E (TTM)
- -14.3
- EPS (TTM)
- -$2.48
Volume 0.93M
Average 1.84M
IMVT Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Immunovant, Inc.NASDAQ: IMVT
Operating Margin · Q2 FY2027 · quarter ended Sep 2026
Operating margin not reported for Q2 FY2027
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Margin history
Percent of revenue · from the income statement
No Operating Margin data reported for this period type.
Operating Margin vs competitors
How IMVT compares with its peers on the latest reported figures
- IMVT's LTM Sep 2026 operating margin of -7488.4% is the lowest of the 6 companies compared; the peer median is 17.6%.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 39.8% | — | +621.2 pp | |
| LTM Sep 2026 | 21.5% | +2.2 pp | +7859.0 pp | |
| LTM Mar 2026 | 17.6% | +107.2 pp | +1139.8 pp | |
| LTM Mar 2026 | -961.9% | -168.3 pp | -673.9 pp | |
| FY2025 | -2113.8% | +1163.9 pp | — | |
| LTM Sep 2026 | -7488.4% | — | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding IMVT) | 17.6% | +54.7 pp | +880.5 pp | |
Competitors are the stored peer set for IMVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 101.81M | 160.26M | 212.93M | 360.92M | 456.66M |
| Selling, General & Admin | 54.23M | 48.02M | 57.28M | 77.24M | 76.24M |
| Operating Expenses | 156.03M | 208.28M | 270.21M | 438.15M | 532.9M |
| Depreciation & Amortization | 126K | 193K | 231K | 377K | 409K |
| EBITDA | (156.69M) | (198.28M) | (258.54M) | (412.57M) | (504.98M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (156.03M) | (208.28M) | (270.21M) | (438.15M) | (532.9M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 7.58M | 24.95M | 24.73M | 25.33M |
| Interest Expense | 0 | 12.48M | 0 | 0 | 0 |
| Other Income / Expenses | (781K) | (2.68M) | 11.44M | 25.2M | 27.51M |
| Income Before Tax | (156.81M) | (210.95M) | (258.77M) | (412.95M) | (505.39M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (84K) | 9K | 567K | 891K | 215K |
| Net Income | (156.73M) | (210.96M) | (259.34M) | (413.84M) | (505.61M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.43) | (1.71) | (1.88) | (2.73) | (2.77) |
| EPS (Diluted) | (1.43) | (1.71) | (1.88) | (2.73) | (2.77) |
| Weighted Avg Shares | 109.68M | 123.08M | 138.1M | 151.57M | 182.42M |
| Weighted Avg Shares (Diluted) | 109.68M | 123.08M | 138.1M | 151.57M | 182.42M |
Immunovant, Inc.
NASDAQ:IMVT
Intrinsic Alpha fair value
Locked
Current Price
$33.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.